{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-100794","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.067831+00:00","generated_at":"2026-06-29T21:46:16.529925+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NextCure Q2 net loss $18M; cash $249.5M; trials NC318/NC410/NC762 on track","bullets":["Net loss of $18.0M for Q2 2021 vs $14.5M in Q2 2020; R&D $11.9M, G&A $6.0M.","Cash, equivalents & marketable securities $249.5M as of June 30, 2021; funded into H2 2023.","NC318 Phase 2 update expected Q4 2021; dosing revised to 800 mg weekly; NSCLC cohort resumed.","NC410 initial Phase 1 data expected Q4 2021; NC762 Phase 1 started, data mid-2022.","CLIA-validated assay for S15+ patient selection available for NC318 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-100794","json":"https://secwatch.observer/filing/0001104659-21-100794.json","markdown":"https://secwatch.observer/filing/0001104659-21-100794.md","text":"https://secwatch.observer/filing/0001104659-21-100794.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465921100794/0001104659-21-100794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465921100794/tm2124228d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:46:16.529925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}